Table 4.
Association of Heart Failure Index Score With Hospital Stay for HF During 4.4 Years of Follow-Up Among 1,015 Participants With Coronary Artery Disease
| Index Score |
% With Events |
Age-Adjusted HR (95% CI) |
p Value | MV-Adjusted HR (95% CI)* |
p Value | MI Size/Treatment- Adjusted HR (95% CI)† |
p Value | EF-Adjusted HR (95% CI)‡ |
p Value | NT-proBNP–adjusted HR (95% CI)§ |
p Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0–2 | 4% (17/397) | reference | — | reference | — | reference | — | reference | — | reference | — |
| 3–4 | 10% (32/313) | 2.4 (1.3–4.4) | 0.003 | 1.9 (0.9–3.9) | 0.08 | 2.0 (1.0–4.2) | 0.06 | 2.0 (0.9–4.1) | 0.07 | 1.9 (0.9–4.1) | 0.09 |
| 5–6 | 24% (63/259) | 6.2 (3.6–10.6) | <0.0001 | 4.1 (2.1–8.1) | <0.0001 | 4.5 (2.2–9.2) | <0.0001 | 3.9 (1.9–8.1) | 0.0003 | 3.0 (1.4–6.5) | 0.006 |
| 7–8 | 48% (22/46) | 13.7 (7.2–25.9) | <0.0001 | 9.1 (4.1–20.1) | <0.0001 | 10.1 (4.4–23.4) | <0.0001 | 9.6 (4.2–22.0) | <0.0001 | 4.3 (1.7–11.0) | 0.002 |
*
Adjusted for age, gender, history of HF, smoking, renal insufficiency, history of hypertension, history of myocardial infarction, history of diabetes, and body mass index.
†
Adjusted for above variables plus: 1) resting wall motion score; 2) prior revascularization; and 3) medication use (beta-blocker, ACE, aspirin, statin).
‡
Adjusted for above variables plus EF.
§
Adjusted for above variables plus log N-terminal part of the pro-B-type natriuretic peptide (NT-proBNP).